

FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 5




FIG. 6

Experimental Protocol

5TGM1






Figure 7





**EFFECT OF PS/2 mAb TREATMENT
ON SPLEEN WEIGHT**




Figure 10

EFFECT OF PS/2 TREATMENT ON SPLENOCYTES
IN MICE WITH 5TGM1 MYELOMA





Figure 11

EFFECT OF PS/2 mAb TREATMENT ON SPLENOCYTE FACS PROFILE


DISEASE FREE



File: do111700.077 Acquisition Date: 17-Nov-00
 Gate: G1 Gated Events: 9624
 Total Events: 10707 Quad Location: 523, 25

Quad	Events	% Gated	% Total	X Mean	Y Mean
UL	9499	98.70	88.72	37.11	1120.67
UR	3	0.03	0.03	5084.96	773.52
LL	122	1.27	1.14	31.88	11.09
LR	0	0.00	0.00


UNTREATED



File: do111700.100 Acquisition Date: 17-Nov-00
 Gate: G1 Gated Events: 9526
 Total Events: 11100 Quad Location: 523, 25

Quad	Events	% Gated	% Total	X Mean	Y Mean
UL	4959	52.06	44.68	84.30	1023.41
UR	1388	14.57	12.50	2377.81	704.20
LL	2163	22.71	19.49	50.53	6.64
LR	1016	10.67	9.15	3619.03	4.05


PS/2 TREATED



File: do111700.120 Acquisition Date: 17-Nov-00
 Gate: G1 Gated Events: 9561
 Total Events: 10934 Quad Location: 523, 25

Quad	Events	% Gated	% Total	X Mean	Y Mean
UL	7868	82.29	71.96	58.00	1139.33
UR	310	3.24	2.84	1922.82	897.47
LL	1171	12.25	10.71	42.10	8.17
LR	212	2.22	1.94	3153.17	3.62

rat IgG2b TREATED



File: do111700.137 Acquisition Date: 17-Nov-00
 Gate: G1 Gated Events: 9595
 Total Events: 10970 Quad Location: 523, 25

Quad	Events	% Gated	% Total	X Mean	Y Mean
UL	4910	51.17	44.76	84.95	975.19
UR	1384	14.42	12.62	1937.36	694.49
LL	1704	17.76	15.53	48.67	7.00
LR	1597	16.64	14.56	3286.15	2.68

Figure 12

EFFECT OF PS/2 mAb TREATMENT ON SPEEN TUMOR BURDEN




Figure 13

EFFECT OF PS/2 mAB TREATMENT ON BONE MARROW CELLS
IN MICE WITH 5TGM1 MYELOMA




Figure 14

**EFFECT OF PS/2 TREATMENT ON BONE MARROW TUMOR BURDEN
mIgG2b POSITIVE CELLS**




Figure 15

14 12 10 8 6 4 2 0
PERCENTAGE OF CELLS

EFFECT OF PS/2 mAb TREATMENT
ON 5TGM1 CELLS IN THE BLOOD




Figure 16

EFFECT OF PS/2 TREATMENT ON BLOOD CHEMISTRY




Figure 17

EFFECT OF PS/2 mAb ON
CIRCULATION mIgG2b LEVELS




Figure 18

**C57/Bl KalmRaj MULTIPLE MYELOMA MODEL
ACUTE TREATMENT PROTOCOLS**




Figure 19

EFFECT OF PS/2 TREATMENT ON IgG2b POSITIVE CELLS
ACUTE TREATMENT MODEL




Figure 20

EFFECT OF ANTI VLA-4 ANTIBODY PS/2
ON TUMOR BURDEN IN SPLEEN




Figure 21

EFFECT OF 6 DAYS OF PS/2 TREATMENT




Figure 22

EFFECT OF 6 DAYS OF PS/2 TREATMENT ON BONE MARROW CELLS




Figure 23

C57/BlK^a Raj Model of Multiple Myeloma Combination Treatment with PS/2 and Melphalan




Figure 24

EFFECT OF TREATMENT ON mIgG2b PLASMA LEVELS




Figure 25

EFFECT OF TREATMENT ON MYELOMA CELLS AT DAY 27




Figure 26

EFFECT OF TREATMENT ON TUMOR BURDEN AT DAY 27





Figure 27

	Day 20	day 27
	PS/2 Plasma levels	PS/2 Plasma levels
8-PS/2	none detected	none detected
9-PS/2	none detected	none detected
10-PS/2	none detected	none detected
11-melphalan+PS/2	none detected	none detected
12-melphalan+PS/2	3.7 μ g/ml	none detected
13-melphalan+PS/2	none detected	none detected

Figure 28

C57/B1K_aLwR_{aj} MODEL OF MULTIPLE MYELOMA
PS/2 AND ANTI VLA4 SMALL MOLECULE
LONG TERM TREATMENT



STGMI CELLS (1E6) INJECTED(I.V.) ON DAY 0
EFFECTIVENESS OF TREATMENT WAS EVALUATED ON DAY 20

GROUPS N=2/GROUP
DISEASE FREE CONTROL
UNTREATED MYELOMA CONTROL
PS/2 -100 micrograms/injection
Sm. Mol . 8809-3 mg/kg, 0.3 mg/kg or 0.03 mg/kg
Sm. Mol. 9257 CONTROL - 3 mg/kg

Figure 29

EFFECT OF LONG TERM TREATMENT ON MYELOMA CELLS




Figure 30

EFFECT OF LONG TERM TREATMENT ON TUMOR BURDEN





Figure 31

C57/BlKaLwRaj MODEL OF MULTIPLE MYELOMA
PS/2 AND ANTI VLA4 SMALL MOLECULE
ACUTE TREATMENT



5TGM1 CELLS (1E6) INJECTED(I.V.) ON DAY 0
PS/2 WAS GIVEN ON DAYS 15,16,17,18,19 AND 20
SMALL MOLECULE WAS GIVEN ON DAYS 15, 16 AND 17
EFFECTIVENESS OF TREATMENT WAS EVALUATED ON DAY 21

GROUPS N=2/GROUP
DISEASE FREE CONTROL,
UNTREATED MYELOMA CONTROL
PS/2 ~100 micrograms/injection
8809--3 mg/kg, 0.3 mg/kg or 0.03 mg/kg
9257 CONTROL -- 3 mg/kg

Figure 32

EFFECT OF ACUTE TREATMENT ON MYELOMA CELLS




Figure 33

EFFECT OF ACUTE TREATMENT ON TUMOR BURDEN




Figure 34

Experimental Protocol

5TGM1 Cells (10^6 /mouse)




Figure 35

Inhibition of Hindleg Paralysis




Figure 36